Comparative Genomic Hybridization Selection of Blastocysts for Repeated Implantation Failure Treatment: A Pilot Study

Abstract

The aim of this study is to determine if the use of preimplantation genetic screening (PGS) by array comparative genomic hybridization (array CGH) and transfer of a single euploid blastocyst in patients with repeated implantation failure (RIF) can improve clinical results. Three patient groups are compared: 43 couples with RIF for whom embryos were selected by array CGH (group RIF-PGS), 33 couples with the same history for whom array CGH was not performed (group RIF NO PGS), and 45 good prognosis infertile couples with array CGH selected embryos (group NO RIF PGS). A single euploid blastocyst was transferred in groups RIF-PGS and NO RIF PGS. Array CGH was not performed in group RIF NO PGS in which 1-2 blastocysts were transferred. One monoembryonic sac with heartbeat was found in 28 patients of group RIF PGS and 31 patients of group NO RIF PGS showing similar clinical pregnancy and implantation rates (68.3% and 70.5%, resp.). In contrast, an embryonic sac with heartbeat was only detected in 7 (21.2%) patients of group RIF NO PGS. In conclusion, PGS by array CGH with single euploid blastocyst transfer appears to be a successful strategy for patients with multiple failed IVF attempts.

Successful experience of preimplantation genetic testing without repeated cryopreservation of embryoswithin 24 hours (clinical case)

“…Сравнительная геномная гибридизация array-CGH оказалась надежным методом ПГТ и широко используется в клиниках репродукции по всему миру [14][15][16][17][18][19][20]. Преимуществом метода array-CGH на биологических чипах является способность выявлять как хромосомные нарушения (анеуплоидии, в том числе и мозаицизм, несбалансированные транслокации и маркерные хромосомы), так и микроделеционные/ микродупликационные синдромы, несбалансированные субтеломерные перестройки одномоментно во всем геноме.…”

New protocol based on massive parallel sequencing for aneuploidy screening of preimplantation human embryos

“…The CGH-BAC microarray has been established worldwide as the gold standard procedure. Furthermore, prospective randomized studies on trophectoderm biopsies support the clear benefits of this scheme on IVF results, improving pregnancy rates and reducing miscarriage significantly [Yang, et al 2012;Yang et al 2015;Forman et al 2013;Scott et al 2013a;Scott et al 2013b;Yin et al 2013;Forman et al 2014;Greco et al 2014;Wells et al 2014;Chen et al 2015;Lee et al 2015;Łukaszuk et al, 2015]. Very recently, PGD laboratories around the world are moving their CCS protocols to next-generation sequencing (NGS) technologies [Yin et al 2013;Fiorentino et al 2014a;Fiorentino et al 2014b;Tan et al 2014;Wang et al 2014;Wells et al 2014;Kung et al 2015;Yang et al 2015].…”

Pre‐implantation genetic testing for aneuploidy: the past, present and future

“…This is particularly important in women of advanced maternal age (AMA) and those with recurrent miscarriages (RM) or repetitive implantation failure (RIF), who have particularly high rates of aneuploidy. 6,11,12 The potential benefits of PGT-A may not be limited to women with poor prognoses. While the prevalence of aneuploid blastocysts increase with age (from 30% in women in their early 30s to nearly 90% in women aged ≥44 years), 4 aneuploidy rates as high as 44.9% have been seen in women aged <35 years with good prognoses.…”